Xenetic Biosciences (NASDAQ:XBIO) signed a definitive all-stock share exchange agreement to acquire all outstanding shares of Santersus AG, creating a combined biotechnology company focused on neutrophil extracellular trap (NET)-targeting therapeutics.
Bristol Myers Squibb (NYSE:BMY) declared a quarterly dividend of $0.63 per share on its $0.10 par value common stock following approval by its Board of Directors.
Viatris (NASDAQ:VTRS) received approval from Japan’s Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy.
Medtronic (NYSE:MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument, expanding the available tools for its Hugo robotic-assisted surgery system in the United States.
HeartSciences (NASDAQ:HSCS) reported fiscal first-quarter 2027 results with no meaningful revenue, a net loss of $3.2 million, and progress updates on its proposed business combination with Fortitude Mining Holdings.
Vera Therapeutics (NASDAQ:VERA) reported final Phase 3 ORIGIN 3 results showing TRUTAKNA (atacicept-vymj) stabilized kidney function and reduced disease progression over two years in adults with primary IgA nephropathy at risk of progression.
Connect Biopharma (NASDAQ:CNTB) reported preliminary topline Phase 2 results from the Seabreeze STAT Asthma study showing rademikibart improved lung function as an add-on treatment for acute asthma exacerbations with type 2 inflammation.
Rocket Pharmaceuticals (NASDAQ:RCKT) received alignment from the U.S. Food and Drug Administration on continued enrollment, dosing, and key design elements for its global Phase 2 pivotal trial of RP-A501 in patients with Danon disease.
Pulse Biosciences (NASDAQ:PLSE) completed enrollment in the PRECISE-BTN clinical study evaluating its nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules.
BioVie (NASDAQ:BIVI) reported topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID, showing statistically significant improvements in pre-specified subgroups with higher baseline fatigue, cognitive impairment, and post-exertional malaise.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, an investigational RNA interference therapy designed to silence PCSK9 and APOC3 genes for patients with mixed hyperlipidemia.
Eli Lilly (NYSE:LLY) will present new clinical trial data on retatrutide, Foundayo (orforglipron), and eloraTZP at the European Association for the Study of Diabetes 2026 meeting in Milan from September 28 to October 2.
